SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
Safe and effective vaccines against SARS-CoV-2 were developed in less than 1 year.
|
9th Influenza Conference 2023
Scientific highlights of the 9th ESWI Influenza Conference
With promising developments in the field of respiratory viral infections, the conference sessions covered hot topics on seasonal, pandemic, and zoonotic influenza viruses, as well as other respiratory viruses such as RSV and SARS-CoV-2.
The hinge-engineered IgG1-IgG3 hybrid subclass IgGh47 potently enhances Fc-mediated function of anti-streptococcal and SARS-CoV-2 antibodies
Streptococcus pyogenes can cause invasive disease with high mortality despite adequate antibiotic treatments. To address this unmet need, we have previously generated an opsonic IgG1 monoclonal antibody, Ab25, targeting the bacterial M protein.
The influenza landscape and vaccination coverage in older adults during theSARS-Cov-2 pandemic: data from Several European Countries and Israel
While influenza and the common cold are both contagious viral respiratory tract illnesses, influenza can be a serious disease that could lead to severe complications and unfavorable outcomes due to broader consequences.
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1
COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of the SARS-CoV-2 XBB.1.5 subvariant.
Perception of government performance during COVID-19 not linked to death rate.
People living in the United States are more likely to report that their government handled the COVID-19 pandemic ‘well’ than any other G7 nation despite having the highest death rate, according to a new report from the Global Listening Project.
Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults
Human infection challenge permits in-depth, early, and pre-symptomatic characterization of the immune response, enabling the identification of factors that are important for viral clearance.
WHO Information Network for Epidemics update on COVID-19
Latest information about circulation, impact and what is needed to prevent infections, severe disease, post-COVID-19 condition and deaths.
Is it bad, is it good, or is IgG4 just misunderstood?
Repeated doses of mRNA vaccines for COVID-19 result in increased proportions of anti-spike antibodies of the IgG4 subclass.
Scientific Papers
News
Article
Omicron BA.2 breakthrough infection elicits CD8+ T cell responses recognizing the spike of later Omicron subvariants
Recent studies have suggested that memory T cells play a critical role in protecting individuals immunized with SARS-CoV-2 vaccines against variants
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike
The European Respiratory Virus Surveillance Summary (ERVISS)
This interactive dashboard provides a weekly integrated epidemiological summary for influenza, RSV and severe acute respiratory syndrome coronavirus 2 for the EU/EEA and the WHO European Region
